BIOAGE LABS, INC. Unrecognized Tax Benefits, Income Tax Penalties and Interest Expense
BIOAGE LABS, INC. (BIOA) reported Unrecognized Tax Benefits, Income Tax Penalties and Interest Expense of $0 for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-24.
Financial Statements › Expense Statement › Interest Expense
us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense · last filed 2026-03-24
- BIOAGE LABS, INC. unrecognized tax benefits, income tax penalties and interest expense for the quarter ending 2024-12-31 was $0.00.
- BIOAGE LABS, INC. unrecognized tax benefits, income tax penalties and interest expense for fiscal 2025 was $0.00.
- BIOAGE LABS, INC. unrecognized tax benefits, income tax penalties and interest expense for fiscal 2024 was $0.00.
- BIOAGE LABS, INC. unrecognized tax benefits, income tax penalties and interest expense for fiscal 2023 was $0.00.
| Period end | Unrecognized Tax Benefits, Income Tax Penalties and Interest Expense 3 month | Unrecognized Tax Benefits, Income Tax Penalties and Interest Expense 9 month | Unrecognized Tax Benefits, Income Tax Penalties and Interest Expense 12 month |
|---|---|---|---|
| 2025-12-31 | $0.00 10-K · filed 2026-03-24 | ||
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-24 | $0.00 10-K · filed 2026-03-24 | |
| 2024-09-30 | $0.00 10-Q · filed 2024-11-07 | ||
| 2023-12-31 | $0.00 10-K · filed 2025-03-20 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Benitec Biopharma Inc. (BNTC) | United States | $0.337B | -10.08 |
| Larimar Therapeutics, Inc. (LRMR) | United States | $0.344B | -1.83 |
| BridgeBio Oncology Therapeutics, Inc. (BBOT) | United States | $0.320B | -3.35 |
| Evommune, Inc. (EVMN) | United States | $0.320B | -5.10 |
| Emergent BioSolutions Inc. (EBS) | United States | $0.347B | -2.43 |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |
| ENANTA PHARMACEUTICALS INC (ENTA) | United States | $0.349B | -6.72 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| Vogenx, Inc. (VOGX) | United States | $0.355B | |
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |